Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma

Evan Cantor, Kyle Wierzbicki, Rohinton S Tarapore, Karthik Ravi, Chase Thomas, Rodrigo Cartaxo, Viveka Nand Yadav, Ramya Ravindran, Amy K Bruzek, Jack Wadden, Vishal John, Clarissa May Babila, Jessica R Cummings, Abed Rahman Kawakibi, Sunjong Ji, Johanna Ramos, Alyssa Paul, Dustin Walling, Marcia Leonard, Patricia Robertson, Andrea Franson, Rajen Mody, Hugh J L Garton, Sriram Venneti, Yazmin Odia, Cassie Kline, Nicholas A Vitanza, Soumen Khatua, Sabine Mueller, Joshua E Allen, Sharon L Gardner, Carl Koschmann, Evan Cantor, Kyle Wierzbicki, Rohinton S Tarapore, Karthik Ravi, Chase Thomas, Rodrigo Cartaxo, Viveka Nand Yadav, Ramya Ravindran, Amy K Bruzek, Jack Wadden, Vishal John, Clarissa May Babila, Jessica R Cummings, Abed Rahman Kawakibi, Sunjong Ji, Johanna Ramos, Alyssa Paul, Dustin Walling, Marcia Leonard, Patricia Robertson, Andrea Franson, Rajen Mody, Hugh J L Garton, Sriram Venneti, Yazmin Odia, Cassie Kline, Nicholas A Vitanza, Soumen Khatua, Sabine Mueller, Joshua E Allen, Sharon L Gardner, Carl Koschmann

Abstract

Background: Diffuse Midline Glioma (DMG) with the H3K27M mutation is a lethal childhood brain cancer, with patients rarely surviving 2 years from diagnosis.

Methods: We conducted a multi-site Phase 1 trial of the imipridone ONC201 for children with H3K27M-mutant glioma (NCT03416530). Patients enrolled on Arm D of the trial (n = 24) underwent serial lumbar puncture for cell-free tumor DNA (cf-tDNA) analysis and patients on all arms at the University of Michigan underwent serial plasma collection. We performed digital droplet polymerase chain reaction (ddPCR) analysis of cf-tDNA samples and compared variant allele fraction (VAF) to radiographic change (maximal 2D tumor area on MRI).

Results: Change in H3.3K27M VAF over time ("VAF delta") correlated with prolonged PFS in both CSF and plasma samples. Nonrecurrent patients that had a decrease in CSF VAF displayed a longer progression free survival (P = .0042). Decrease in plasma VAF displayed a similar trend (P = .085). VAF "spikes" (increase of at least 25%) preceded tumor progression in 8/16 cases (50%) in plasma and 5/11 cases (45.4%) in CSF. In individual cases, early reduction in H3K27M VAF predicted long-term clinical response (>1 year) to ONC201, and did not increase in cases of later-defined pseudo-progression.

Conclusion: Our work demonstrates the feasibility and potential utility of serial cf-tDNA in both plasma and CSF of DMG patients to supplement radiographic monitoring. Patterns of change in H3K27M VAF over time demonstrate clinical utility in terms of predicting progression and sustained response and possible differentiation of pseudo-progression and pseudo-response.

Keywords: H3K27M; ONC201; circulating tumor DNA; diffuse midline glioma; liquid biopsy.

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

Figures

Fig. 1
Fig. 1
Landscape of patient samples and H3K27M variant allele fraction (VAF) by time point.
Fig. 2
Fig. 2
(A-B) Correlation of tumor area change from baseline with CSF and plasma VAF percentage change from baseline (P value by Pearson correlation.) (C-D) H3K27M VAF by location in CSF (all time points) (C) and plasma (D, t-test.).
Fig. 3
Fig. 3
(A-B) Correlation of VAF change (delta: baseline-final time point VAF) to PFS (days of treatment) for CSF (A) and plasma (B, Pearson correlation) for nonrecurrent patients. (C-D) Progression free survival (PFS) (days of treatment) for nonrecurrent patients when patients are separated by VAF delta (increase or decrease from first to last value) for CSF (C) and plasma (D).
Fig. 4
Fig. 4
(A) Patients with tDNA peak (25% increase) and relation to tumor progression on tumor imaging (B) and days prior to progression by sample type. (C) Increase in VAF predicts progression in CSF and correlates with progression in a 10-year-old female with DIPG treated with ONC201.
Fig. 5
Fig. 5
(A) Pseudo-progression on tumor area by MRI (red dotted box) is not reflected in cf-tDNA H3K27M VAF reduction in a 6-year-old DMG patient with long-term response to ONC201. (B) A 13-year-old male with spinal H3K27M-mutant glioma demonstrates plasma VAF increase prior to radiologic progression. The drop in tumor area (gray plot) occurred during administration of bevacizumab, which caused reduction in tumor edema/area and contrast enhancement.

References

    1. Karremann M, Gielen GH, Hoffmann M, et al. . Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol. 2018; 20(1):123–131.
    1. Sturm D, Witt H, Hovestadt V, et al. . Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012; 22(4):425–437.
    1. Schroeder KM, Hoeman CM, Becher OJ. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatr Res. 2014; 75(1-2):205–209.
    1. Castel D, Philippe C, Calmon R, et al. . Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015; 130(6):815–827.
    1. Brandes AA, Tosoni A, Spagnolli F, et al. . Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol. 2008; 10(3):361–367.
    1. Wang Y, Springer S, Zhang M, et al. . Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci USA. 2015; 112(31):9704–9709.
    1. Stallard S, Savelieff MG, Wierzbicki K, et al. . CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response. Acta Neuropathol Commun. 2018; 6(1):80.
    1. Bruzek AK, Ravi K, Muruganand A, et al. . Electronic DNA analysis of CSF cell-free tumor DNA to quantify multi-gene molecular response in pediatric high-grade glioma. Clin Cancer Res. 2020; 26(23):6266–6276.
    1. Miller AM, Shah RH, Pentsova EI, et al. . Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019; 565(7741):654–658.
    1. Panditharatna E, Kilburn LB, Aboian MS, et al. . Clinically relevant and minimally invasive tumor surveillance of pediatric diffuse midline gliomas using patient-derived liquid biopsy. Clin Cancer Res. 2018; 24(23):5850–5859.
    1. Izquierdo E, Proszek P, Pericoli G, et al. . Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. Neurooncol Adv. 2021; 3(1):vdab013.
    1. Ishizawa J, Zarabi SF, Davis RE, et al. . Mitochondrial ClpP-Mediated proteolysis induces selective cancer cell lethality. Cancer Cell. 2019; 35(5):721–737.e9.
    1. Greer YE, Porat-Shliom N, Nagashima K, et al. . ONC201 kills breast cancer cells in vitro by targeting mitochondria. Oncotarget. 2018; 9(26):18454–18479.
    1. Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/TRAIL-dependent manner. Cancer Res. 2015; 75(7):1423–1432.
    1. Allen JE, Krigsfeld G, Mayes PA, et al. . Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013; 5(171):171ra–17117.
    1. Prabhu VV, Madhukar NS, Gilvary C, et al. . Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism. Clin Cancer Res. 2019; 25(7):2305–2313.
    1. Arrillaga-Romany I, Odia Y, Prabhu VV, et al. . Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol. 2020; 22(1):94–102.
    1. Hall MD, Odia Y, Allen JE, et al. . First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. J Neurosurg Pediatr. 2019; 23(6):1–7.
    1. Chi AS, Tarapore RS, Hall MD, et al. . Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol. 2019; 145(1):97–105.
    1. Li J, Zhao S, Lee M, et al. . Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma. Sci Adv. 2020; 6(42):1–14.
    1. Welton JL, Loveless S, Stone T, von Ruhland C, Robertson NP, Clayton A. Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. J Extracell Vesicles. 2017; 6(1):1369805.
    1. Peng Y, Zheng D, Zhang X, et al. . Cell-free mitochondrial DNA in the CSF: a potential prognostic biomarker of anti-NMDAR encephalitis. Front Immunol. 2019; 10(6):103.
    1. Mackay A, Burford A, Carvalho D, et al. . Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell. 2017; 32(4):520–537 e525.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する